Medical Condition News

RSS

FDA grants EarlySense marketing clearance for EverOn Touch system

EarlySense announced today that its EverOn Touch system has been cleared for marketing by the U.S. Food and Drug Administration. The FDA clearance covers several key additions to the traditional EverOn contact-free patient supervision system value proposition. For the first time, the EverOn system includes an online display that alerts medical staff regarding a patient's motion level and verifies patient turns as indicated by nurses. Identifying low patient movement and then turning patients methodically are key elements in the prevention of pressure ulcers, the most costly patient safety risk in U.S. hospitals.

21 Jun 2010

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.

21 Jun 2010

Toshiba's Aquilion ONE dynamic volume CT system improves clinical pathway for patients in ERs

Emergency departments are challenged to streamline patient diagnoses and treatment for a variety of conditions and require a CT system capable of imaging patients quickly, accurately and safely. Toshiba America Medical Systems, Inc.'s Aquilion® ONE 320-detector row CT system is designed for such settings and used to evaluate a range of patients, including cardiac, neuro, stroke and pediatric.

21 Jun 2010

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. announced guidance today regarding the Company's planned pivotal Phase III trial for palifosfamide in metastatic soft tissue sarcoma, including details of the proposed study's design, timing and regulatory review.

21 Jun 2010

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Recently, oral cancer survivor Jeanna Richelson, organized the first Chattanooga Oral Cancer Awareness Walk, which raised donations for the Oral Cancer Foundation, and much needed awareness of a disease that too few Americans know about. According to the foundation's executive director Brian Hill, "I don't believe there has ever been an oral cancer walk that was this successful in its first year. This was an absolutely amazing effort by Jeanna and those who helped her make this possible."

21 Jun 2010

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.

21 Jun 2010

FDA accepts ev3's Pipeline Embolization Device PMA for expedited review

ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.

21 Jun 2010

Researchers develop new drugs that relieve cancer pain without side effects

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current pain-treatments like morphine.

21 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites.

21 Jun 2010

Federal funds available to support specialized training curriculum on Mental Health Procedures Act

Approximately $500,000 is available in federal American Recovery and Reinvestment Act funds to support a specialized training curriculum on the Mental Health Procedures Act of 1976 for judges, law enforcement, psychologists, social workers and other professionals in the criminal justice system.

21 Jun 2010

Severity of appendicitis can be predicted from blood sample, shows thesis

The symptoms of appendicitis are often diffuse and it can be difficult to obtain an accurate diagnosis early in the course of the disease. It may be possible to predict the severity from a blood sample, and in this way determine the treatment on an individual basis. This is the conclusion of a thesis presented at the University of Gothenburg, sweden.

21 Jun 2010

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

Hepatic artery thrombosis, which is the most common vascular complication after living donor liver transplantation, can result in graft loss and devastating consequences. Surgical techniques are suggested to an important factor in causing HAT. Despite improvements in surgical techniques, arterial reconstruction in LDLT has a high risk of thrombosis.

21 Jun 2010

Incidental findings in brain imaging can be managed ethically and cost-effectively: UBC researchers

The increasing number of incidental findings in brain imaging can be managed ethically and cost-effectively by screening study participants based on gender, age and family history, according to University of British Columbia researchers.

21 Jun 2010

Studies explore effects of fructose consumption on metabolic parameters in humans

New research released today from Rippe Lifestyle Institute and the University of Central Florida shows no difference between table sugar and high fructose corn syrup on weight gain or any changes in risk factors for metabolic syndrome or insulin resistance, a precursor to diabetes. Abstracts for the two studies are the first to provide longer term prospective data exploring the effects the normal consumption of fructose has on metabolic parameters in humans.

21 Jun 2010

Achieving remission in patients lessens burden of RA on societies with aging populations: Study

Achieving disease remission in patients with rheumatoid arthritis provides superior outcomes across measures of socio-economic importance including work productivity and quality of life according to results presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. These Austrian findings are reported in addition to improvements in measures of physical functioning, when compared with RA patients achieving low disease activity.

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

Magic Power Coffee can dangerously lower blood pressure, warns FDA

The U.S. Food and Drug Administration is warning consumers that Magic Power Coffee, an instant coffee product marketed as a dietary supplement for sexual enhancement, contains an active drug ingredient that can dangerously lower blood pressure.

21 Jun 2010

Medical Condition News

FDA grants EarlySense marketing clearance for EverOn Touch system

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

Toshiba's Aquilion ONE dynamic volume CT system improves clinical pathway for patients in ERs

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

FDA accepts ev3's Pipeline Embolization Device PMA for expedited review

Researchers develop new drugs that relieve cancer pain without side effects

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Federal funds available to support specialized training curriculum on Mental Health Procedures Act

Severity of appendicitis can be predicted from blood sample, shows thesis

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

Incidental findings in brain imaging can be managed ethically and cost-effectively: UBC researchers

Studies explore effects of fructose consumption on metabolic parameters in humans

Achieving remission in patients lessens burden of RA on societies with aging populations: Study

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Magic Power Coffee can dangerously lower blood pressure, warns FDA

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News